Morepen Laboratories Q1 FY25 results (Apr–Jun 2024) and concall

Morepen Labs reported a historic Q1 FY25, achieving its highest ever EBITDA and significant PAT growth, driven by strong performance in both pharma and medical devices segments. The company successfully completed a ₹200 crores QIP, which will fund capacity expansion for APIs and medical devices, aiming for full operation within 12-18 months. Management expressed bullishness on future growth and margin expansion, emphasizing backward integration and global market opportunities.